LSTA (Lisata Therapeutics) Owner Earnings per Share (TTM): -1.71 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSTA Lisata Therapeutics Inc LSTA
27 GF Score
Price $1.00
! 4 Warning Signs
View Full Analysis

What is Lisata Therapeutics Owner Earnings per Share (TTM)?

Lisata Therapeutics LSTA -3.88% 27 Owner Earnings per Share (TTM) is -1.71 as of Mar. 2026. GuruFocus rates LSTA with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 206 Biotechnology companies, Lisata Therapeutics ranks worse than 485436.41% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lisata Therapeutics's Owner Earnings per Share (TTM) ended in Mar. 2026 was $-1.71. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Lisata Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:



LSTA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 24.95
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Lisata Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.50. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86. It's PE Ratio (TTM) ratio for today is At Loss.

Lisata Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.51. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.93. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Lisata Therapeutics Owner Earnings per Share (TTM) Related Terms


Lisata Therapeutics Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Lisata Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics Owner Earnings per Share (TTM) Chart

Lisata Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.74 -6.97 -2.60 -2.47 -2.03

Lisata Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -2.09 -2.15 -2.03 -1.71

LSTA vs CYCN, OSRH, ICU: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Lisata Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Price-to-Owner-Earnings falls into.


LSTA
27GF Score
Lisata Therapeutics Inc LSTA
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lisata Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Lisata Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -16.35
Depreciation, Depletion and Amortization 0.11
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.11
Change In Working Capital 0.96
Shares Outstanding (Diluted Average) 9.01

1. Start with "Net Income" from income statement. Lisata Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.35 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Lisata Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was $0.11 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Lisata Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.11 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Lisata Therapeutics's 5-Year Average Maintenance Capital Expenditure = $0.11 Mil

5. "Change In Working Capital" is from cashflow statement. Lisata Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was $0.96 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Lisata Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 9.006 Mil.

Lisata Therapeutics's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -16.351 +0.105+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.112+0.963)/9.006
=-1.71

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.00/-1.71
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -1.71 mean?
Lisata Therapeutics (LSTA) has a Owner Earnings per Share (TTM) of -1.71 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Lisata Therapeutics. According to the industry distribution chart, Lisata Therapeutics ranks #999999 out of 206 companies in the Biotechnology industry.
Is Lisata Therapeutics' Owner Earnings per Share (TTM) too high?
Lisata Therapeutics' current Owner Earnings per Share (TTM) is -1.71. Based on the distribution chart, Lisata Therapeutics ranks #999999 out of 206 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lisata Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' Owner Earnings per Share (TTM) compare to CYCN and OSRH?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #999999 out of 206 companies for Owner Earnings per Share (TTM). This places Lisata Therapeutics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 24.95, based on 206 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Lisata Therapeutics. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 24.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current Owner Earnings per Share (TTM) is -1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (LSTA) has a current Owner Earnings per Share (TTM) of -1.71. The current Owner Earnings per Share (TTM) is -1.71. Lisata Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current Owner Earnings per Share (TTM) is -1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Other Exchanges 0HS8:UK8NE:Germany
Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
27GF Score

Get the complete analysis for LSTA

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price